



**FIGURE 112-3** Staging of pancreatic cancer, and survival according to stage. AJCC, American Joint Committee on Cancer. (Illustration by Stephen Millward.)

Study	Comparator Arm	No. of Patients	Survival	
			PFS/DFS (months)	Median Survival (months)
ESPAC-1, Neoptolemos et al: N Engl J Med 350:1200, 2004	Chemotherapy (folinic acid + bolus 5-FU) vs no chemotherapy	289	PFS 15.3 vs 9.4. ( $p = .02$ )	20.1 vs 15.5 (HR 0.71; 95% CI 0.55–0.92; $p = .009$ )
CONKO 001, Oettle et al: JAMA 297:267, 2007	Gemcitabine vs observation	368	Median DFS 13.4 vs 6.9 ( $p < .001$ )	22.1 vs 20.2 ( $p = .06$ )
ESPAC-3, Neoptolemos et al: JAMA 304:1073, 2010	5-FU/LV vs gemcitabine	1088		23 vs 23.6 (HR 0.94; 95% CI 0.81–1.08, $p = .39$ )

**Abbreviations:** CI, confidence interval; CONKO, Charité Onkologie; DFS, disease-free survival; ESPAC, European Study Group for Pancreatic Cancer; 5-FU, 5-fluorouracil; HR, hazard ratio; LV, leucovorin; PFS, progression-free survival.